<DOC>
	<DOC>NCT02472769</DOC>
	<brief_summary>Two different dose levels will be evaluated in two different birth weight categories, compared to placebo with regards to safety and tolerability.</brief_summary>
	<brief_title>IBP-9414 for the Prevention of Necrotizing Enterocolitis</brief_title>
	<detailed_description />
	<mesh_term>Enterocolitis, Necrotizing</mesh_term>
	<mesh_term>Enterocolitis</mesh_term>
	<criteria>1. Gestational age ≤32 weeks 2. Birth weight: a) ≤ 2,000 g and b) ≤ 1,000 g. 3. &lt; 48 hours of age. 4. Written informed consent from the patient's legally authorized representative(s). 1. Participation in an additional interventional clinical trial in which an investigational drug will be administered. 2. Infants in extremis to whom no further intensive care is offered by attending neonatologist (e.g., infant being provided only hospice/comfort care). 3. Congenital or acquired gastrointestinal pathology. 4. Other conditions of the infant, which in the opinion of the attending neonatologist, preclude participation.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>48 Hours</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>